Tuberculosis Immunology
TDM needed for macrophage infection with M. tuberculosis
Published in TB and Outbreaks Week, October 14th, 2003
"The persistence of tuberculosis within pulmonary granulomatous lesions is a complex phenomenon, with bacterial survival occurring in a focal region of high immune activity," scientists in the United States noted.
"In part, the survival of the organism may be linked to the ability of the surface glycolipid trehalose 6,6'-dimycolate (TDM; cord factor) to inhibit fusion events between phospholipid vesicles inside the host macrophage," explained J. Indrigo and colleagues at the University of Texas. "At the same time, TDM contributes to macrophage activation and a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Drug Development
Mycobacterial arabinogalactan linkage disaccharide analogs block cell wall biosynthesis - Drug Development
Potent inhibitors of M. tuberculosis TMPK developed - Infectious Disease
Rab5 activity, iron access needed for mycobacterial arrest of phagosome maturation - Malaria Therapy
Azadirachta indica derivatives not practical for malaria treatment - Tuberculosis Latent Infection
M. tuberculosis Rel needed for latent TB infection - AIDS Prevention
Studies to look at role of alcohol in HIV risk in heterosexual women - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
